CAT-140 Dumps are totally changed by CA-Technologies. Download from killexams.com today

killexams.com give Latest and 2022 refreshed CAT-140 practice questions with practice questions Questions and Answers for new points. Practice our CAT-140 Dumps Questions and braindumps to Improve your insight and finish your CAT-140 test with High Marks. We ensure your accomplishment in the Test Center, covering every last one of the motivations behind test and foster your Knowledge of the CAT-140 test. Pass without question with our real issues.

Exam Code: CAT-140 Practice exam 2022 by Killexams.com team
CA SiteMinder r12 Professional
CA-Technologies Professional exam syllabus
Killexams : CA-Technologies Professional exam syllabus - BingNews https://killexams.com/pass4sure/exam-detail/CAT-140 Search results Killexams : CA-Technologies Professional exam syllabus - BingNews https://killexams.com/pass4sure/exam-detail/CAT-140 https://killexams.com/exam_list/CA-Technologies Killexams : GovCon Wire

Dedrone has named Ben Wenger, a two-decade enterprise software sales veteran, as chief revenue officer and appointed Mary-Lou Smulders, strategic

Michael Barnes, former senior strategic account executive for the Department of Agriculture at Salesforce (NYSE: CRM), has joined Google's (Nasdaq:…

Mark Fabian, former strategic account executive at CA Technologies' federal business, has joined The Ambit Group as vice president of growth,…

Fri, 18 Nov 2022 10:00:00 -0600 en-US text/html https://www.govconwire.com/tag/ca-technologies/
Killexams : Business Technology Management (BComm)

Nicole Um

Major in Business Technology Management
Minor in Computer Science

Being part of an association, not only have I gained great leadership skills, time management skills and industry knowledge, I’ve also met amazing people and had so much fun!

Sat, 24 Sep 2022 14:27:00 -0500 en text/html https://www.concordia.ca/academics/undergraduate/business-technology-management.html
Killexams : ICAN Unveils New Examination Syllabus, Seals Deal with Tertiary Institutions

The Institute of Chartered Accountants of Nigeria (ICAN) has launched a new syllabus for its professional examination. The new syllabus which takes effect from March 2021 was developed in line with the, “institute’s resolve to continue to produce future-ready Chartered Accountants with skills and competences desired by the market.”

ICAN disclosed this in a statement obtained at the weekend.

The ICAN President, Onome Joy Adewuyi, who unveiled the new curriculum said the revised syllabus captured subjects on emerging technologies that are disrupting the accounting profession, such as block chain technology, artificial intelligence, machine learning and internet of things, among others.

She explained further that new trends in the Nigerian environment such as the Finance Act 2020 which introduced new developments in the country’s tax system and the new Companies and Allied Matters Act (CAMA 2020) also presented added impetus for the review.

According to her, “a Chartered Accountant worth its salt is not just an expert in the technical aspect of the profession but should be furnished with soft skills including effective communication, integrity, accuracy and good professional judgment.”

She added that the current syllabus was reviewed in 2018 but the rapidly changing environment necessitated a revisit of the status quo from the five-year policy of the syllabus review to a more regular one that proactively responds to the demands of the market.

The review also necessitated the restructuring of various levels of the institute’s examinations to reflect the new changes in the syllabus and equally expanded the contents of the various subjects against the backdrop of the new normal.

“While retaining the 15 subjects, there are now four subjects at the Foundation level as against the former five, six at Skills as against five and retained the five subjects at the Professional level.

Meanwhile the Institute has signed the Mutual Cooperation Agreement (MCATI) with two tertiary institutions to deepen the standards of learning and dissemination of Accounting knowledge in Nigeria. The Institutions are: Adeleke University Ede, Osun State and the Federal University, Nekede, Owerri, Imo State, thus bringing the number of Institutions under the scheme to 23. All the 23 institutions are obligated to incorporate the requirements of the new syllabus in their curriculum.

The agreement meant that accounting students in the two institutions, and the 21 before them, would study using the integrated accounting curriculum of ICAN, National Universities Commission (NUC) and National Board for Technical Education (NBTE).

Accounting graduates from the Institutions would be granted 10 subject exemptions instead of seven subjects under the normal ICAN accreditation scheme.

Tue, 01 Nov 2022 12:00:00 -0500 en-US text/html https://www.thisdaylive.com/index.php/2020/09/28/ican-unveils-new-examination-syllabus-seals-deal-with-tertiary-institutions/
Killexams : Pliant Technologies Appoints Southern California Manufacturers' Representative

Pliant Technologies (opens in new tab) has appointed Vision2 West Marketing as its Manufacturers’ Representative for Southern California.

“The Southern California market is very important to us, and partnering with Vision2 West puts Pliant Technologies in a great position to increase brand awareness and market share,” said Gary Rosen, vice president of global sales for Pliant Technologies. “Vision2 West’s seasoned team of sales and support professionals will help ensure that all current and future customers receive optimal customer service and support, and we look forward to working with the Vision2 team.”

Fri, 02 Dec 2022 01:56:00 -0600 en text/html https://www.avnetwork.com/news/pliant-technologies-appoints-southern-california-manufacturers-representative
Killexams : PRINCIPAL TECHNOLOGIES CORPORATE UPDATE

VANCOUVER, BC, Nov. 29, 2022 /CNW/ - Principal Technologies Inc. (the "Company") (TSXV: PTEC.P), which is building a diverse portfolio of investments in healthcare technologies companies, is pleased to provide this corporate update to shareholders.

The Company is pleased to announce that it has initiated proceedings of a potential $500,000 private placement financing that will be finalized as soon as the delayed financial filings are delivered, which is expected by December 15, 2022 or earlier, and the CTO is removed. The funds will be used in parts to secure options for participations in targets that will increase the intrinsic value of the company. Details about the financing will follow in due course.

The company is also pleased to announce it has expanded its advisory board by adding high profile individuals from the fields of business & finance as well as technology.

Dr. Gerald (Geri) Rainer, former CEO of one of the largest Swiss Private Banks and trustee on several international multi billion dollar trusts (among other experience), and Dr. Ivo Ivanovski, former Information Technology Minister of the Republic of Macedonia.

Besides from Dr. Rainer's business acumen and his generally extensive international network, the Company expects benefitting in particular from his institutional investor contacts and their financial backing of larger transactions and participations we plan on conducting in the new year.

Dr. Ivanovski, who is currently among others member of the Advisory Committee of the prestigious World Information Technology and Services Alliance (WITSA), will be instrumental in the appraisal of international technology trends, especially with regard to cloud-related healthcare technologies solutions for hospitals where large telecommunication companies hold strong footholds.

His Serene Highness Prince Alfred of Liechtenstein, Chairman of the Board of Directors (the "Board"), as well as the rest of the Board, warmly welcome Geri and Ivo to the company. Dr. Rainer, will serve as Chairman of the Advisory Board.

In the meantime, the Company's portfolio companies, E&E CRO Consulting and Vision Surgery AI (VSAI), are performing very well. These investments are further described in the news releases dated July, 8, 2021 and March 10, 2022.

VSAI is currently marketing a placement based on a substantially higher valuation than the one used when we participated earlier this year (at the time valuation was USD$20 million) as they have advanced their development accordingly.

The Company earned a dividend of approx. EUR 97k compared to the EUR 100k paid in cash purchase consideration the year prior from E&E CRO.

The Company will provide more in depth information, especially on acquisition targets for 2023, after the closing of the proposed financing.

About Principal Technologies Inc.

Principal Technologies Inc. (TSXV: PTEC.P), is building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential, that have achieved regional success. Principal Technologies will also focus on companies that have IP capable of enhancing medical treatment quality and efficiency, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. In addition to providing growth capital, the company also aims to support the growth of its portfolio with the expertise of its management team, board, and advisers. 
Learn more: https://principal-technologies.com/

ON BEHALF OF THE BOARD OF DIRECTORS:

Jerry Trent, Chief Executive Officer
Principal Technologies Inc.

Cautionary Note Regarding Forward-Looking Information

This news release contains statements which constitute "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"), including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding: (a) expectations regarding whether the Transaction will be consummated including whether the conditions to the consummation of the Transaction; (b) the timing for completing the Transaction, if at all, and the conditions to such transaction; and (c) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the resulting issuer. Among the key factors that could cause genuine results to differ materially from those projected in the forward-looking statements are the following the ability to consummate the Transaction; the ability to obtain requisite regulatory and shareholder approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and regulations both locally and in foreign jurisdictions; compliance with extensive government regulation; the risks and uncertainties associated with foreign markets; and the diversion of management time on the Transaction. These forward-looking statements may be affected by risks and uncertainties in the business of E&E, the Company and general market conditions, including COVID-19.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, genuine results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause genuine results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. E&E and the Company do not intend, and do not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.

Completion of the Transaction is subject to a number of conditions, including but not limited to TSXV acceptance. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the filing statement prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Principal Technologies Inc.

For further information: Investor inquiries, please contact: [email protected]

Mon, 28 Nov 2022 23:03:00 -0600 en text/html https://www.newswire.ca/news-releases/principal-technologies-corporate-update-834505545.html
Killexams : Professional Diagnostics Market in Depth Analysis,…

Being a proficient and comprehensive, “Professional Diagnostics Market” survey report puts a light on primary and secondary drivers, market share, leading segments, possible sales volume, and geographical analysis. This market research report contains thorough analysis of the market structure along with forecast of the various segments and sub-segments of the market. A numerous markets, marketing strategies, trends, future products and rising opportunities are taken into consideration while studying market and preparing this report. The chief areas covered in the wide ranging Professional Diagnostics market report include market definition, market segmentation, competitive analysis and research methodology.

Professional diagnostics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to grow at a CAGR of 6.70% in the above-mentioned forecast period.

Professional diagnostics are basically the diagnostic methods which provide faster detection of diseases such as cancer, malaria, infections, blood glucose levels and others in an individual. The sole objective of the professional tests is to provide early diagnosis and hence an early treatment and have successfully replaced many laboratory and clinical experiments.

 Download sample PDF of the Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-professional-diagnostics-market

THANKSGIVING WEEK SALE!!!!   

Get UPTO 35%. OFF ON GLOBAL REPORTS… OFFER VALID TILL 30 NOV 2022

To succeed in this swiftly changing market place, businesses must take up an all-inclusive Professional Diagnostics Market analysis report solution. This market report looks over the market with respect to general market conditions, market improvement, market scenarios, development, cost and profit of the specified market regions, position and comparative pricing between major players. The data and information included in this business report not only aids business make data-driven decisions but also assures maximum return on investment (ROI). A range of steps are used while generating Professional Diagnostics Market document by taking the inputs from a dedicated team of researchers, analysts and forecasters.

Segmentation:

Professional diagnostics market is segmented on the basis of product type and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of product type, the professional diagnostics market is segmented into immunochemistry, clinical microbiologypoint of care test(POCT) and hematology and hemostasis.
  • Professional diagnostics market has also been segmented based on the end users into hospital, diagnostic centers and others.

Fundamental Aim of Professional Diagnostics Market Report

In the Professional Diagnostics market, every company has goals, but this report focus in on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.

  • Major alterations to the Professional Diagnostics Market in the near future.
  • Notable Market rivals around the world.
  • The Professional Diagnostics Market’s Future Scope and Product Outlook
  • Future-promising emerging markets.
  • The Market Presents Difficult Challenges and Threats.
  • Sales data and profiles of the world’s leading Professional Diagnostics manufacturers

THANKSGIVING WEEK SALE!!!!                                                                    

Get UPTO 35%. OFF ON GLOBAL REPORTS… OFFER VALID TILL 30 NOV 2022

Access Full Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-professional-diagnostics-market

What benefits does DBM research study is going to provide?

Latest industry influencing trends and development scenario

Open up New Markets

To Seize powerful market opportunities

Key decision in planning and to further expand market share

Identify Key Business Segments, Market proposition & Gap Analysis

Assisting in allocating marketing investments

Key Market Players:

Some of the major players operating in the professional diagnostics market report are F. Hoffman-La Roche Ltd, Abbott, Danaher, Thermo Fischer., Siemens., Abaxis, Hologic Inc., Bio-Rad Laboratories Inc., BD, Enzo Biochem Inc, Trivitron Healthcare, Shenzhen New Industries Biomedical Engineering Co., Ltd., Sinduri Biotec, Sekisui Diagnostics, Nipro Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and  Werfen among others.

 Attractions of The Professional Diagnostics Market Report: –

  • Latest market dynamics, development trends and growth opportunities are presented along with industry barriers, developmental threats and risk factors
  • The forecast Professional Diagnostics Market data will help in the feasibility analysis, market size estimation and development
  • The report serves as a complete guide which micro monitors all vital Professional Diagnostics Market
  • A concise market view will provide ease of understanding.
  • Nut Oil Market Competitive market view will help the players in making a right move

Key Questions Answered

  • What impact does COVID-19 have made on Global Professional Diagnostics Market Growth & Sizing?
  • Who are the Leading key players and what are their Key Business plans in the Global Professional Diagnostics Market?
  • What are the key concerns of the five forces analysis of the Global Professional Diagnostics Market?
  • What are different prospects and threats faced by the dealers in the Global Professional Diagnostics Market?
  • What are the strengths and weaknesses of the key vendors?

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-professional-diagnostics-market

Reasons to Purchase this Report:

  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value USD Million and volume Units Million data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, latest developments, SWOT analysis, and strategies employed by the major market players

Table of Content:

  • Part 01: Executive Summary
  • Part 02: Scope of The Report
  • Part 03: Professional Diagnostics Market Landscape
  • Part 04: Professional Diagnostics Market Sizing
  • Part 05: Professional Diagnostics Market Segmentation By Product
  • Part 06: Five Forces Analysis
  • Part 07: Customer Landscape
  • Part 08: Geographic Landscape
  • Part 09: Decision Framework
  • Part 10: Drivers and Challenges
  • Part 11: Market Trends
  • Part 12: Vendor Landscape
  • Part 13: Vendor Analysis

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-professional-diagnostics-market

About Us:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

corporatesales@databridgemarketresearch.com

Mon, 28 Nov 2022 21:33:00 -0600 en text/html https://www.pharmiweb.com/press-release/2022-11-29/professional-diagnostics-market-in-depth-analysis-global-trends-new-technologies-regional-analysi
Killexams : ClearSign Technologies Corporation Receives Concluding Purchase Order for California Refinery Multi Heater Project

Order Comprised of 16 Burners, Control Equipment and Spare Parts

TULSA, Okla., Nov. 30, 2022 /PRNewswire/ -- ClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company"), an emerging leader in industrial combustion and sensing technologies that Excellerate energy, operational efficiency and safety while dramatically reducing emissions, today announced that the Company has received the concluding purchase order to proceed with the last phase of the 20 burner project announced on March 29, 2022 for a California refinery.

ClearSign Logo (PRNewsFoto/ClearSign Combustion Corporation) (PRNewsfoto/ClearSign Combustion Corporation)

The purchase order is for the manufacture and delivery of the remaining 16 burners, control equipment and spare parts.  This purchase order follows the purchase order for a multi burner test and four burners required for that testing, and other ancillary items announced on September 1, 2022. Work associated with the September 1st purchase order has progressed into the final testing and demonstration phase.  The 20 burners are to be installed into two heaters at the customers refinery site in California in 2023 during their scheduled maintenance shutdown.

"We are very pleased about how this project is progressing, and to have received the final stage of this significant commercial purchase order," said Jim Deller, Ph.D., Chief Executive Officer of ClearSign.  "We had previously mentioned that the timeline for this project had been shortened and are glad to be able to meet the needs of our customer.  This installation of our best in class ultra low NOx technology will be significant for us as it is in our target market of California and at a notable refinery."

About ClearSign Technologies Corporation

ClearSign Technologies Corporation designs and develops products and technologies for the purpose of improving key performance characteristics of industrial and commercial systems, including operational performance, energy efficiency, emission reduction, safety and overall cost-effectiveness. Our patented technologies, embedded in established OEM products as ClearSign Core™, and ClearSign Eye™ and other sensing configurations, enhance the performance of combustion systems and fuel safety systems in a broad range of markets, including the energy (upstream oil production and down-stream refining), commercial/industrial boiler, chemical, petrochemical, transport and power industries. For more information, please visit www.clearsign.com.

Cautionary note on forward-looking statements

All statements in this press release that are not based on historical fact are "forward-looking statements." You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "would," "should," "could," "may," "will" or other similar expressions. While management has based any forward-looking statements included in this press release on its current expectations on the Company's strategy, plans, intentions, performance, or future occurrences or results, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, that could cause genuine results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, our ability to successfully install our burners in the California refinery and complete the anticipated project within the updated timeline, general business and economic conditions, the performance of management and our employees, our ability to obtain financing, competition, whether our technology will be accepted and adopted and other factors identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission and available at www.sec.gov and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of genuine results. The Company disclaims any intention to, and, except as may be required by law, undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter becomes aware.

Cision

View original content to get multimedia:https://www.prnewswire.com/news-releases/clearsign-technologies-corporation-receives-concluding-purchase-order-for-california-refinery-multi-heater-project-301689950.html

SOURCE ClearSign Technologies Corporation

Tue, 29 Nov 2022 23:32:00 -0600 en-US text/html https://www.yahoo.com/now/clearsign-technologies-corporation-receives-concluding-133000154.html
Killexams : IBEX Technologies Full Year 2022 Earnings: EPS: CA$0.067 (vs CA$0.031 in FY 2021)

Key Financial Results

  • Revenue: CA$7.89m (up 49% from FY 2021).

  • Net income: CA$1.67m (up 120% from FY 2021).

  • Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue.

  • EPS: CA$0.067 (up from CA$0.031 in FY 2021).

earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

IBEX Technologies shares are down 15% from a week ago.

Risk Analysis

Be aware that IBEX Technologies is showing 2 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Wed, 16 Nov 2022 21:16:00 -0600 en-US text/html https://finance.yahoo.com/news/ibex-technologies-full-2022-earnings-110137390.html
Killexams : Reliq Health Technologies, Inc. Announces 15 New Skilled Nursing Facility Clients in California

HAMILTON, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. RHTRQHTF ("Reliq" or the "Company"), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a contract with a network of 15 Skilled Nursing Facilities (SNFs) in California. This contract is expected to add a further 1,000 new patients per month or 12,000 new patients per year to Reliq's iUGO Care platform beginning in 2023.

"We are very pleased to be expanding into the Skilled Nursing Facility market in California," said Dr. Lisa Crossley, CEO at Reliq Health Technologies, Inc. "Reliq will be providing our iUGO Care Transitional Care Management (TCM), Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Behavioural Health Integration (BHI) solutions to help Excellerate post-discharge health outcomes and reduce readmissions, while also generating new revenue streams for the facilities. The Company will provide TCM to newly discharged patients at a rate of $60 per patient, with recurring revenue from RPM, CCM and BHI of $65/patient per month, at 75% gross margin. We will begin onboarding patients with these facilities in early 2023. Once all 15 facilities are live we expect to onboard over 1,000 of their newly discharged patients every month. The Skilled Nursing space is currently one of our fastest growing market segments and we are excited to help SNFs provide new healthcare services to their patients to drive better outcomes."

Reliq Health
Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

ON BEHALF OF THE BOARD
"Dr. Lisa Crossley"
CEO and Director

For further information please contact:

Company Contact
Investor Relations at ir@reliqhealth.com

US Investor Relations Contact
Investor Relations
Lytham Partners, LLC
Ben Shamsian
New York | Phoenix
646-829-9701
shamsian@lythampartners.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause genuine and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. genuine results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.


© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Wed, 16 Nov 2022 18:10:00 -0600 text/html https://www.benzinga.com/pressreleases/22/11/g29760809/reliq-health-technologies-inc-announces-15-new-skilled-nursing-facility-clients-in-california
Killexams : ABC Technologies Holdings GAAP EPS of -$0.20, revenue of $0.32M

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Thu, 10 Nov 2022 21:05:00 -0600 en text/html https://seekingalpha.com/news/3906493-abc-technologies-holdings-gaap-eps-of-0_20-revenue-of-0_32m
CAT-140 exam dump and training guide direct download
Training Exams List